READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma

READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma

Background: Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelu...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Antonuzzo, M. Maruzzo, U. De Giorgi, D. Santini, R. Tambaro, S. Buti, F. Carrozza, F. Calabrò, G. Di Lorenzo, G. Fornarini, R. Iacovelli, D. Cullurà, C. Messina, L. Cerbone, G. Fazzi, F. Venturini, R. Colasanto, A. Necchi, S. Bracarda
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
avelumab
urothelial carcinoma
real-world study
immune checkpoint inhibitor
maintenance
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000468
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items